Genmab A/S : Transactions with shares and linked securi

Genmab A/S : Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons


March 7, 2021 –
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in
Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given
Genmab A/S power of attorney on their behalf to publish trading in
Genmab shares by the company’s managerial employees and their closely associated persons.
Contact:          
& Communications
For Investor Relations:
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on

Related Keywords

Denmark , Copenhagen , Køavn , Kalvebod Brygge , Marisol Peron , Andrew Carlsen , Exchange Commission , Eu Press , Company Announcement , Market Abuse , Implementing Regulation , Senior Vice President , Global Investor Relations , Investor Relations , Senior Director , Annual Report , Horizon Therapeutics , Genmabas Stock Exchange , News , Information , Press Release , In , Accordance , With , Article , 19 , Of , Regulation , Son , Market , Abuse , Hand , Implementing , This , Document , Discloses , The , Data , Transactions , Made , Genmab , Made Gmab Dk0010272202 , டென்மார்க் , கோபெந்ஹேகந் , மரிசோல் பராந் , ஆண்ட்ரூ கார்ல்சன் , பரிமாற்றம் தரகு , யூ ப்ரெஸ் , நிறுவனம் அறிவிப்பு , மூத்தவர் துணை ப்ரெஸிடெஂட் , உலகளாவிய முதலீட்டாளர் உறவுகள் , முதலீட்டாளர் உறவுகள் , மூத்தவர் இயக்குனர் , ஆண்டு அறிக்கை , அடிவானம் சிகிச்சை , செய்தி , தகவல் , ப்ரெஸ் வெளியீடு , இல் , பொருத்தம் , உடன் , கட்டுரை , ஆஃப் , ஒழுங்குமுறை , ஆன் , சந்தை , மற்றும் , இது , ஆவணம் , தி , தகவல்கள் , பரிவர்த்தனைகள் , செய்து ,

© 2025 Vimarsana